Zoledronic acid

Bibliography

• Coleman RE. Risks and benefits of bisphosphonates. Br J Cancer 2008;98(11):1736-40
   PubMed Web of Science ®Google Scholar
• Neville-Webbe HL, Coleman RE. Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur J Cancer 2010;46:1211-22
   PubMed Web of Science ®Google Scholar
• Coleman RE, Body J-J, Gralow JR, Lipton A. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies. Cancer Treat Rev 2008;34(Suppl 1):S31-42
   PubMed Web of Science ®Google Scholar
• Holen I, Coleman RE. Bisphosphonates as treatment of bone metastases. Curr Pharm Des 2010;16:1262-71
   PubMed Web of Science ®Google Scholar
• Dieli F, Vermijlen D, Fulfaro F, Targeting human gammadeltaT cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007;67:7450-7
   PubMed Web of Science ®Google Scholar
• Pfister T, Atzpodien E, Bohrmann B, Bauss F. Acute renal effects of intravenous bisphosphonates in the rat. Basic Clin Pharmacol Toxicol 2005;97(6):374-81
   PubMed Web of Science ®Google Scholar
• Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998;19(1):80-100
   PubMed Web of Science ®Google Scholar
• Chaudhary M, Tamta A, Sehgal R. Evaluation of toxicity profile of zoledronic acid in Wistar rat; a sub-chronic toxicity study. Internet J Toxicol 2009;6(2)
   Google Scholar
• Pfister T, Atzpodien E, Bauss F. The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology 2003;191(2-3):159-67
   PubMed Web of Science ®Google Scholar
• Luhe A, Kunkele KP, Haiker M, Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety. Toxicol In Vitro 2008;22(4):899-909
   PubMed Web of Science ®Google Scholar
• Levy S, Fayez I, Taguchi N, Pregnancy outcome following in utero exposure to bisphosphonates. Bone 2009;44(3):428-30
   PubMed Web of Science ®Google Scholar
• Kohno N, Aogi K, Minami H, Zoledronic acid significantly reduces skeletal complications compared with placebo in japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314-21
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Kaminski M, Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in thetreatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer 2003;98:1735-44
   PubMed Web of Science ®Google Scholar
• Black D, Delmas PD, Eastell R, Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22
   PubMed Web of Science ®Google Scholar
• Boonen S, Black DM, Colon-Emeric CS, Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly. Postmenopausal Women with Osteoporosis Aged 75 and Older. J Am Geriatr Soc 2010;58:292-9
   PubMed Web of Science ®Google Scholar
• Reid I, Brown J, Burckhardt P, Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-66
   PubMed Web of Science ®Google Scholar
• Kunzmann V, Bauer E, Feurle J, Stimulation of gammadeltaT cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000;96:384-92
   PubMed Web of Science ®Google Scholar
• Gober HJ, Kitstowska M, Angman L, Human T cell receptor gamma delta cells recognize endogenous mevalonate metabolites in tumour cells. J Exp Med 2002;197:163-8
   Web of Science ®Google Scholar
• Musto P, Petrucci MT, Bringhen S, A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer 2008;113(7):1588-95
   PubMed Web of Science ®Google Scholar
• Carteni G, Bordonaro R, Giotta F, Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a Multicenter Clinical Trial. Oncologist 2006;11(7):841-8
   PubMed Web of Science ®Google Scholar
• Peter R, Mishra V, Fraser WD. Severe hypocalcaemia after being given intravenous bisphosphonate. Br Med J 2004;328(7435):335-6
   PubMed Web of Science ®Google Scholar
• Singh D, Khaira NS, Sekhon JS. Symptomatic hypocalcaemia after treatment with zoledronic acid in a patient with multiple myeloma. Ann Oncol 2004;15(12):1848
   PubMed Web of Science ®Google Scholar
• Jones SG, Dolan G, Lengyel K, Myers B. Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions. Br J Haematol 2002;119(2):576-7
   PubMed Web of Science ®Google Scholar
• Breen TL, Shane E. Prolonged hypocalcemia after treatment with zoledronic acid in a patient with prostate cancer and vitamin D deficiency. J Clin Oncol 2004;22(8):1531-2
   PubMed Web of Science ®Google Scholar
• Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006;17(6):897-907
   PubMed Web of Science ®Google Scholar
• Hypponen E, Power C. Hypovitaminosis D in British adults at age 45 y: nationwide cohort study of dietary and lifestyle predictors. Am J Clin Nutr 2007;85(3):860-8
   PubMed Web of Science ®Google Scholar
• Wang-Gillam A, Miles DA, Hutchins LF. Evaluation of vitamin D deficiency in breast cancer patients on bisphosphonates. Oncologist 2008;13(7):821-7
   PubMed Web of Science ®Google Scholar
• Pearce SH, Cheetham TD. Diagnosis and management of vitamin D deficiency. Br Med J 2010;340:b5664
   PubMed Web of Science ®Google Scholar
• Available from: http://www.pharma.us.novartis.com/product/pi/pdf/Zometa.pdf
   Google Scholar
• Kennel KA, Drake MT. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc 2009;J84(7):632-7, quiz 8
   Google Scholar
• Chennuru S, Koduri J, Baumann MA. Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid. Int Med J 2008;38(8):635-7
   Google Scholar
• Major P, Lortholary A, Hon J, Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19(2):558-67
   PubMed Web of Science ®Google Scholar
• Coleman RTH, Cameron D, Bell R, Zoledronic acid is well tolerated and can be safely administered with adjuvant chemotherapy-first safety data from the AZURE trial (BIG01/04). San Antonio Breast Cancer Symposium. 2006. Breast Cancer Res Treat 2006;100(Suppl 1): abstract 2080
   Google Scholar
• Berenson J, Hirschberg R. Safety and convenience of a 15-minute infusion of zoledronic acid. Oncologist 2004;9(3):319-29
   PubMed Web of Science ®Google Scholar
• Markowitz GS, Fine PL, Stack JI, Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003;64(1):281-9
   PubMed Web of Science ®Google Scholar
• Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003;349(17):1676-9
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Tchekmedyian NS, Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004;100(12):2613-21
   PubMed Web of Science ®Google Scholar
• Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int 2008;74(11):1385-93
   PubMed Web of Science ®Google Scholar
• Marx RE. Pamidronate (Aredia) And zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-17
   PubMed Web of Science ®Google Scholar
• Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003;15:4253-4
   Google Scholar
• Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34
   PubMed Web of Science ®Google Scholar
• Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65:2397-410
   PubMed Web of Science ®Google Scholar
• Schwartz HC. Osteonecrosis of the jaws: a complication of cancer chemotherapy. Head Neck Surg 1982;4:251-3
   PubMedGoogle Scholar
• Mirzai R, Chang C, Greenspan A, Gershwin ME. The pathogenesis of osteonecrosis and the relationships to corticosteroids. J Asthma 1999;36:77-95
   PubMed Web of Science ®Google Scholar
• Donoghue AM. Bisphosphonates and osteonecrosis: analogy to phossy jaw. Med J Aust 2005;183:163-4
   PubMed Web of Science ®Google Scholar
• Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 2005;63:682-9
   PubMed Web of Science ®Google Scholar
• Marx RE. Uncovering the cause of “phossy jaw” Circa 1858 to 1906: oral and maxillofacial surgery closed case files-case closed. J Oral Maxillofac Surg 2008;66:2356-63
   PubMed Web of Science ®Google Scholar
• Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006a;102:433-41
   PubMed Web of Science ®Google Scholar
• Khosla S, Burr D, Cauley J, Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91
   PubMed Web of Science ®Google Scholar
• Migliorati CA, Casiglia J, Epstein J, Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 2005;136:1658-68
   PubMed Web of Science ®Google Scholar
• Ruggiero SL, Gralow J, Marx RE, Practical guidelines for the prevention, diagnosis and treatment of osteonecrosis of the jaw in patients with cancer. J Clin Oncol Prac 2006b;2:7-14
   PubMedGoogle Scholar
• Weitzman R, Sauter N, Eriksen EF, Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients – May 2006. Crit Rev Oncol Hematol 2007;62:148-52
   PubMed Web of Science ®Google Scholar
• Altundag K, Bulut N, Tezcan E, Tooth extraction: is it inciting event or sequela of osteonecrosis of the jaws associated with intravenous bisphosphonates? J Oral Maxillofac Surg 2007;65:154
   PubMed Web of Science ®Google Scholar
• Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates – histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006;35:155-60
   PubMed Web of Science ®Google Scholar
• Ruggiero SL, Dodson TB, Assael LA, American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg 2009;67:2-12
   PubMed Web of Science ®Google Scholar
• Colella G, Campisi G, Fusco V. (American Association of Oral and Maxillofacial Surgeons position paper: bisphosphonate-related osteonecrosis of the jaws-2009 update: the need to refine the BRONJ definition. J Oral Maxillofac Surg 2009;67:2698-9
   PubMed Web of Science ®Google Scholar
• Junquera L, Gallego L. Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant? J Oral Maxillofac Surg 2008;66:1516-17
   PubMed Web of Science ®Google Scholar
• Yarom N, Fedele S, Lazarovici TS, Elad S. Is exposure of the jawbone mandatory for establishing the diagnosis of bisphosphonate-related osteonecrosis of the jaw? J Oral Maxillofac Surg 2009;67(5 Suppl):2-12
   Google Scholar
• Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-75
   PubMed Web of Science ®Google Scholar
• Wood J, Bonjean K, Ruetz S, Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-61
   PubMed Web of Science ®Google Scholar
• Bouquot JE, Mcmahon RE. Neuropathic pain in maxillofacial osteonecrosis. J Oral Maxillofac Surg 2000;58:1003-20
   PubMed Web of Science ®Google Scholar
• Christodoulou C, Pervena A, Klouvas G, Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009;76:209-11
   PubMed Web of Science ®Google Scholar
• Brunello A, Saia G, Bedogni A, Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone 2009;44:173-5
   PubMed Web of Science ®Google Scholar
• Ayllon J, Launay-Vacher V, Medioni J, Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile? Ann Oncol 2009;20:600-1
   PubMed Web of Science ®Google Scholar
• Greuter S, Schmid F, Ruhstaller T, Thurlimann B. Bevacizumab-associated osteonecrosis of the jaw. Ann Oncol 2009;19:2091-2
   Web of Science ®Google Scholar
• Estilo CL, Fornier M, Farooki A, Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 2008;26:4037-8
   PubMed Web of Science ®Google Scholar
• Brown JE, Barrios CH, Diel IJ, Incidence and outcomes of osteonecrosis of the jaw from an integrated analysis of three pivotal randomized double-blind, double-dummy phase 3 trials comparing denosumab and zoledronic acid for treatment of bone metastases in advanced cancer patients or myeloma. Cancer and Bone Society Proceedings 2010: abstract 15
   Google Scholar
• Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 2007;41:318-20
   PubMed Web of Science ®Google Scholar
• Scheper MA, Badros A, Chaisuparat R, Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol 2009;144:667-76
   PubMed Web of Science ®Google Scholar
• Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst 2007;99(13):1016-24
   PubMed Web of Science ®Google Scholar
• AAOMS. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-76
   PubMed Web of Science ®Google Scholar
• Almazrooa SA, Woo SB. Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: a review. J Am Dent Assoc 2009;140:864-75
   PubMed Web of Science ®Google Scholar
• Hoff AO, Toth BB, Altundag K, Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008;23:826-36
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kastritis E, Bamia C, Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009;20:117-20
   PubMed Web of Science ®Google Scholar
• Ripamonti CI, Manniezzo M, Campa T, Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009;20(1):137-45
   PubMed Web of Science ®Google Scholar
• Corso A, Varettoni M, Zappasodi P, A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 2007;21:1545-8
   PubMed Web of Science ®Google Scholar
• Schwartz HC. Bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg 2005;63:1555-6
   PubMed Web of Science ®Google Scholar
• Landis BN, Richter M, Osteonecrosis of the jaw after treatment with bisphosphonates: is irreversible, so the focus must be on prevention. Br Med J 2006;333:982-3
   PubMed Web of Science ®Google Scholar
• Stanton DC, Balasanian E. Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases. J Oral Maxillofac Surg 2009;67:943-50
   PubMed Web of Science ®Google Scholar
• Pazanias M, Compston J, Huang CL-H. Atrial fibrillation and bisphosphonate therapy. J Bone Miner Res 2010;25:2-10
   PubMed Web of Science ®Google Scholar
• Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med 2007;356:1895-96
   PubMed Web of Science ®Google Scholar
• Camm AJ. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis. Clin Ther 2010;32:426-36
   PubMed Web of Science ®Google Scholar
• Lyles KW, Colon-Emeric CS, Magaziner JS, ; for the HORIZON Recurrent Fracture Trial. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 2007;357:1799-809
   PubMed Web of Science ®Google Scholar
• Lipton A. The safety of zoledronic acid. Expert Opin Drug Saf 2007;6:305-13
   PubMed Web of Science ®Google Scholar
• Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006;17:897-907
   PubMed Web of Science ®Google Scholar
• Colucci A, Modorati G, Miserocchi E, Anterior uveitis complicating zoledronic acid infusion. Ocul Immunol Inflamm 2009;17:267-8
   PubMed Web of Science ®Google Scholar
• Kilickap S, Ozdamar Y, Altundag MK, Dizdar O. A case report: zoledronic acid-induced anterior uveitis. Med Oncol 2008;25:238-40
   PubMed Web of Science ®Google Scholar
• Banal F, Briot K, Ayoub G, Unilateral anterior uveitis complicating zoledronic acid therapy in prostate cancer. J Rheumatol 2008;35:2458-9
   PubMed Web of Science ®Google Scholar
• Moore MM, Beith JM. Acute unilateral anterior uveitis and scleritis following a single infusion of zoledronate for metastatic breast cancer. Med J Aust 2008;188:370-1
   PubMed Web of Science ®Google Scholar
• Durnian JM, Olujohungbe A, Kyle G. Bilateral acute uveitis and conjunctivitis after zoledronic acid therapy. Eye (Lond) 2005;19:221-2
   PubMed Web of Science ®Google Scholar
• Huang J, Meixner L, Fernandez S, McCutchan JA. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS. 2009;23:51-7
   PubMed Web of Science ®Google Scholar
• Woo TC, Joseph DJ, Wilkinson R. Serious ocular complications of zoledronate. Clin Oncol (R Coll Radiol) 2006;18:545-46
   PubMed Web of Science ®Google Scholar
• Lee P, van der Wall H, Siebel MJ. Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy. J Endocrinol Invest 2007;30:590-7
   PubMed Web of Science ®Google Scholar
• Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008;358:304-06
   PubMedGoogle Scholar
• Kwek EB, Goh SK, Koh JS, An emerging pattern of sub-trochanteric stress fractures: a long term complication of alendronate therapy? Injury 2008;39:224-31
   PubMed Web of Science ®Google Scholar
• Black DM, Kelly MP, Genant HK, Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. New Engl J Med 2010;362:1761-71
   PubMed Web of Science ®Google Scholar
• Visekruna M, Wilson D, McKiernan E. Severely suppressed bone turnover and atypical bone fragility. J Clin Endocrinol Metab 2008;93:2948-52
   PubMed Web of Science ®Google Scholar
• Whyte MP. Atypical femoral fractures, bisphosphonates and adult hypophosphatasia. J Bone Miner Res 2009;24:1132-34
   PubMed Web of Science ®Google Scholar
• Nieves JW, Cosman F. Atypical subtrochanteric and femoral fractures and possible association with bisphosphonates. Curr Osteoporos Rep 2010;8:34-9
   PubMedGoogle Scholar
• Giusti A, Hamdy NAT, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy. A systematic review of case/case series studies. Bone 2010;47(2):169-80
   PubMed Web of Science ®Google Scholar
• Girgis CM, Sher D, Siebel MJ. Atypical femoral fractures and bisphosphonate use. N Engl J Med 2010;362:1848-49
   PubMed Web of Science ®Google Scholar
• Abrahamsen B. Adverse effects of bisphosphonates. Calcif Tissue Int 2010;86:421-35
   PubMed Web of Science ®Google Scholar
• Seeman. To stop or not to stop, that is the question. Osteoporos Int 2009;20:187-95
   PubMed Web of Science ®Google Scholar
• Black DM, Kelly MO, Genant HK, Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. New Engl J Med 2010;362:1761-71
   PubMed Web of Science ®Google Scholar
• Biswas PN, Wilton L, Harris S, Pharmacovigilance study of alendronate in England. Osteoporos Int 2003;14:507-14
   PubMed Web of Science ®Google Scholar
• Body JJ, Coleman R, Clezardin P, International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur J Cancer 2007;43(5):852-8
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R, A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68
   PubMed Web of Science ®Google Scholar
• Gnant M, Mlineritsch B, Schippinger W, Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360:679-91
   PubMed Web of Science ®Google Scholar